185 related articles for article (PubMed ID: 1291340)
1. [A case of esophageal carcinoma with hypercalcemia caused by PTH-rP--the effect of therapy on the bone and calcium metabolism].
Nakayama Y; Okuno S; Miki T; Nishizawa Y; Morii H
Nihon Naibunpi Gakkai Zasshi; 1992 Dec; 68(12):1294-9. PubMed ID: 1291340
[TBL] [Abstract][Full Text] [Related]
2. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
[TBL] [Abstract][Full Text] [Related]
3. Effect of aminohydroxypropylidene diphosphonate on the bone metabolism of patients with parathyroid adenoma.
Ishimura E; Miki T; Koyama H; Harada K; Nakatsuka K; Inaba M; Nishizawa Y; Morii H
Horm Metab Res; 1993 Sep; 25(9):493-7. PubMed ID: 8225204
[TBL] [Abstract][Full Text] [Related]
4. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
Budayr AA; Zysset E; Jenzer A; Thiébaud D; Ammann P; Rizzoli R; Jaquet-Müller F; Bonjour JP; Gertz B; Burckhardt P
J Bone Miner Res; 1994 Apr; 9(4):521-6. PubMed ID: 8030440
[TBL] [Abstract][Full Text] [Related]
5. Bone resorption and renal calcium reabsorption in renal cell carcinoma-bearing mice: the effects of bisphosphonate.
Weissglas M; Löwik C; Schamhart D; Theuns H; Kurth KH; Papapoulos S
BJU Int; 2007 Jun; 99(6):1530-3. PubMed ID: 17428243
[TBL] [Abstract][Full Text] [Related]
6. The effect of low calcium diet, mithramycin, and dichlorodimethylene bisphosphonate on humoral hypercalcemia of malignancy in nude mice transplanted with the canine adenocarcinoma tumor line (CAC-8).
Rosol TJ; Capen CC
J Bone Miner Res; 1987 Oct; 2(5):395-405. PubMed ID: 2971305
[TBL] [Abstract][Full Text] [Related]
7. Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D.
Horwitz MJ; Tedesco MB; Sereika SM; Syed MA; Garcia-Ocaña A; Bisello A; Hollis BW; Rosen CJ; Wysolmerski JJ; Dann P; Gundberg C; Stewart AF
J Bone Miner Res; 2005 Oct; 20(10):1792-803. PubMed ID: 16160737
[TBL] [Abstract][Full Text] [Related]
8. Hypercalcemic complication in patients with oral squamous cell carcinoma.
Iwase M; Takemi T; Manabe M; Nagumo M
Int J Oral Maxillofac Surg; 2003 Apr; 32(2):174-80. PubMed ID: 12729778
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound.
Green JR; Müller K; Jaeggi KA
J Bone Miner Res; 1994 May; 9(5):745-51. PubMed ID: 8053405
[TBL] [Abstract][Full Text] [Related]
10. Parathyroid hormone-related protein induced coupled increases in bone formation and resorption markers for 7 years in a patient with malignant islet cell tumors.
Takeuchi Y; Fukumoto S; Nakayama K; Tamura Y; Yanagisawa A; Fujita T
J Bone Miner Res; 2002 May; 17(5):753-7. PubMed ID: 12009004
[TBL] [Abstract][Full Text] [Related]
11. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy.
Rizzoli R; Thiébaud D; Bundred N; Pecherstorfer M; Herrmann Z; Huss HJ; Rückert F; Manegold C; Tubiana-Hulin M; Steinhauer EU; Degardin M; Thürlimann B; Clemens MR; Eghbali H; Body JJ
J Clin Endocrinol Metab; 1999 Oct; 84(10):3545-50. PubMed ID: 10522993
[TBL] [Abstract][Full Text] [Related]
12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
13. A case of temporary severe disequilibrium hypercalcemia.
Kogawa K; Inaba M; Okuno Y; Nishizawa Y; Morii H
Miner Electrolyte Metab; 1994; 20(3):163-8. PubMed ID: 7816007
[TBL] [Abstract][Full Text] [Related]
14. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
Wimalawansa SJ
Cancer; 1994 Apr; 73(8):2223-30. PubMed ID: 8156530
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo.
Uy HL; Mundy GR; Boyce BF; Story BM; Dunstan CR; Yin JJ; Roodman GD; Guise TA
Cancer Res; 1997 Aug; 57(15):3194-9. PubMed ID: 9242449
[TBL] [Abstract][Full Text] [Related]
16. Conflicting actions of parathyroid hormone-related protein and serum calcium as regulators of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase expression in a nude rat model of humoral hypercalcemia of malignancy.
Michigami T; Yamato H; Suzuki H; Nagai-Itagaki Y; Sato K; Ozono K
J Endocrinol; 2001 Nov; 171(2):249-57. PubMed ID: 11691644
[TBL] [Abstract][Full Text] [Related]
17. Hyperparathyroidism, humoral hypercalcemia of malignancy, and the anabolic actions of parathyroid hormone and parathyroid hormone-related protein on the skeleton.
Stewart AF
J Bone Miner Res; 2002 May; 17(5):758-62. PubMed ID: 12009005
[TBL] [Abstract][Full Text] [Related]
18. Treatment of humoral hypercalcemia of malignancy in rats with inhibitors of carbonic anhydrase.
Brown GM; Morris CA; Mitnick MA; Insogna KL
J Bone Miner Res; 1990 Oct; 5(10):1037-41. PubMed ID: 1964358
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms and treatment of hypercalcemia of malignancy.
Clines GA
Curr Opin Endocrinol Diabetes Obes; 2011 Dec; 18(6):339-46. PubMed ID: 21897221
[TBL] [Abstract][Full Text] [Related]
20. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
Lee SH; Huang TS; Hsieh SJ
Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
